Vaccine Composition Formulated with a Novel -Derived Exopolysaccharides Adjuvant Provided High Protection against .

UNLABELLED

A vaccine that effectively targets methicillin-resistant (MRSA) is urgently needed, and has been the focus of studies by numerous research groups, but with limited success to date. Recently, our team found that exopolysaccharides derived from probiotic strain WXD030 as an adjuvant-formulated OVA could upregulate IFN-γ and IL-17 expression in CD4 T cells. In this study, we developed a vaccine (termed rMntC-EPS) composed of antigen MntC and   exopolysaccharides, which conferred high levels of protection against infection.

METHODS

Six-eight-week-old female mice were vaccinated with purified rMntC-EPS30. The immune protection function of rMntC-EPS30 was assessed by the protective effect of rMntC-EPS30 to -induced pulmonary and cutaneous infection in mice, bacterial loads and H&E in injury site, and ELISA for inflammation-related cytokines. The protective mechanism of rMntC-EPS30 was assessed by ELISA for IgG in serum, cytokines in the spleen and lungs of vaccinated mice. In addition, flow cytometry was used for analyzing cellular immune response induced by rMntC-EPS30. For confirmation of our findings, three kinds of mice were used in this study: IL-17A knockout mice, IFN-γ knockout mice and TCRγ/δ knockout mice.

RESULTS

rMntC-EPS30 conferred up to 90% protection against pulmonary infection and significantly reduced the abscess size in the cutaneous model, with clearance of the pathogen. The rMntC-EPS vaccine could induce superior humoral immunity as well as significantly increase IL-17A and IFN-γ production. In addition, we found that rMntC-EPS vaccination induced robust Th 17/γδ T 17 primary and recall responses. Interestingly, this protective effect was distinctly reduced in the IL-17A knockout mice but not in IFN-γ knockout mice. Moreover, in TCRγ/δ knockout mice, rMntC-EPS vaccination neither increased IL-17A secretion nor provided effective protection against infection.

CONCLUSIONS

These data demonstrated that the rMntC formulated with a novel -derived Exopolysaccharides adjuvant provided high protection against . The rMntC-EPS vaccine induced γδ T cells and IL-17A might play substantial roles in anti- immunity. Our findings provided direct evidence that rMntC-EPS vaccine is a promising candidate for future clinical application against -induced pulmonary and cutaneous infection.